---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-003026"
form_type: "8-K"
ticker: "INBP"
cik: "0001016504"
company_name: "INTEGRATED BIOPHARMA INC"
filed_at: "2022-02-10T23:59:59+00:00"
generated_at: "2026-06-27T08:59:43.729954+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Integrated BioPharma (INBP) Q1 net income $1.0M vs $1.2M; revenue up 2.1%

## Summary
- Revenue for quarter ended Dec 31, 2021: $14.6M, up 2.1% YoY from $14.3M.
- Operating income fell to $0.7M from $1.2M; net income $1.0M vs $1.2M.
- EPS basic unchanged at $0.04; diluted $0.03 vs $0.04.
- Six-month revenue down 7.1% to $27.3M; net income $1.5M vs $2.3M.
- Co-CEOs attribute 6-month decline to prior year's COVID-related safety stock and demand.

## SEC filing metadata
- accession: 0001437749-22-003026
- form_type: 8-K
- ticker: INBP
- cik: 0001016504
- company_name: INTEGRATED BIOPHARMA INC
- filed_at: 2022-02-10T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1016504/000143774922003026/0001437749-22-003026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1016504/000143774922003026/inbp20220209_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-003026
- JSON: https://secwatch.observer/filing/0001437749-22-003026.json
- Plain text: https://secwatch.observer/filing/0001437749-22-003026.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.